No Data
Subdued Growth No Barrier To GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Price
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Wells Fargo analyst Stan Berenshteyn maintains $GoodRx(GDRX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 58.7% and a
Why Big Pharma Is Betting on Telehealth Strategies
GoodRx Holdings Shares Are Trading Higher Possibly After Eli Lilly Said Zepbound 2.5 Mg and 5 Mg Single-dose Vials Are Available for Self-pay for Patients With an On-label Prescription. GoodRx Offers Savings for Tirzepatide, the Generic Form of...
GoodRx to Participate in Upcoming Investor Conferences
GoodRx Holdings Price Target Maintained With a $10.00/Share by RBC Capital